TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis-Reference-Cited by-同舟云学术

TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis

Published:2023-09 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Pisano Chiara,Turco Fabio^ORCID,Arnaudo Elena,Fea Elena,Vanella Paola,Ruatta Fiorella,Filippi Roberto^ORCID,Brusa Federica,Prati Veronica,Vana Federica,Mennitto Alessia^ORCID,Cattrini Carlo,Vignani Francesca^ORCID,Dionisio Rossana,Icardi Massimiliano,Guglielmini Pamela,Buosi Roberta,Stevani Ilaria,Vormola Roberto,Numico Gianmauro,Depetris Ilaria,Comandone Alessandro,Gennari Alessandra,Airoldi Mario,Rossi Maura^ORCID,Vellani Giorgio,Ortega Cinzia^ORCID,Tucci Marcello,Maio Massimo Di,Buttigliero Consuelo

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference36 articles.

1. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial;Clarke;Ann Oncol,2019

2. The prognostic value of pain in castration-sensitive prostate cancer;Iacovelli;Prostate Cancer Prostatic Dis,2020

3. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial;Gravis;Lancet Oncol,2013

4. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

5. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial;Kyriakopoulos;J Clin Oncol,2018